Reprimo基因多態(tài)性與肺癌的研究進(jìn)展(2)
由上可見,Reprimo基因多態(tài)性表達(dá)與肺癌的關(guān)系探討仍屬空白,研究其關(guān)系對于肺癌發(fā)生的分子機(jī)制以及評估肺癌的發(fā)生、發(fā)展及預(yù)后具有重要意義。
參考文獻(xiàn)
[1] Nici L.The role of pulmonary rehabilitation in the lung cancer patient [J].Semin Respir Crit Care Med,2009,30(6):670-674.
[2] Liu G,Zhou W,Christiani DC.Molecular epidemiology of non-small cell lung cancer.Semin Respir Crit Care Med,2005,26(3):265-272.
[3] Fasching PA,Gayther S,Pearce L,et al.Role of genetic polymorphisms and ovarian cancer susceptibility[J].Mol Oncol,2009,3(2):171-181.
, 百拇醫(yī)藥
[4] Ohki R,Nemoto J,Murasawa H,et al.Reprimo,a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase[J].Biol Chem,2000,275(30):22627-22630.
[5] Bernal C,Aguayo F,Villarroel C,Vargas M,Díaz I,Ossandon FJ,Santibáez E,Palma M,Aravena E,Barrientos C,Corvalan AH.Reprimo as a potential biomarker for early detection in gastric cancer.Clin Cancer Res,2008 Oct 1,14(19):6264-9.
[6] Sato N,F(xiàn)ukushima N,Matsubayashi H,Iacobuzio-Donahue CA,Yeo CJ,Goggins M.Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.,2006 Jul 15,107(2):251-7
, 百拇醫(yī)藥
[7] Hamilton JP,Sato F,Jin Z,Greenwald BD,Ito T,Mori Y,Paun BC,Kan T,Cheng Y,Wang S,Yang J,Abraham JM,Meltzer SJ.Reprimo methylation is a potential biomarker of Barrett''s-Associated esophageal neoplastic progression.Clin Cancer Res,2006 Nov 15,12(22):6637-42.
[8] Takahashi T,Suzuki M,Shigematsu H,Shivapurkar N,Echebiri C,Nomura M,Stastny V,Augustus M,Wu CW,Wistuba II,Meltzer SJ,Gazdar AF.Aberrant methylation of Reprimo in human malignancies.Int J Cancer,2005 Jul 1,115(4):503-10.
, http://www.www.srpcoatings.com
[9] Suzuki M,Shigematsu H,Takahashi T,Shivapurkar N,Sathyanarayana UG,Iizasa T,F(xiàn)ujisawa T,Gazdar AF.Aberrant methylation of Reprimo in lung cancer.Lung Cancer,2005 Mar,47(3):309-14.
[10] 王海,等.5-AzadC聯(lián)合TSA對人胃癌SGC-7901細(xì)胞生長及 Reprimo基因表達(dá)的影響.安徽科技大學(xué)學(xué)報,2012,47(1):1-4
[11] 羅峻,等.S100A2、Reprimo在胃腺癌中的表達(dá)及其臨床意義.中華實(shí)驗(yàn)外科雜志,2008,25(6):754-755.
[12] 姜蕊,于世英.非小細(xì)胞肺癌中Reprimo以及14-3-3 Σ基因啟動子異常甲基化檢測.腫瘤防治研究,2009,36(2):106-109.
, http://www.www.srpcoatings.com
[13] Ye Z,Parry JM.Identification of polymorphisms in the human Reprimo gene using public EST data.Teratog Carcinog Mutagen[J],2002,22(6):485-493.
[14] Beasley WD,Beynon J,Jenkins GJ,et al.Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer:a case-control disease association study[J].Int J Colorectal Dis,2008,23(4):375-381., 百拇醫(yī)藥(陳賢華 胡宏波)
參考文獻(xiàn)
[1] Nici L.The role of pulmonary rehabilitation in the lung cancer patient [J].Semin Respir Crit Care Med,2009,30(6):670-674.
[2] Liu G,Zhou W,Christiani DC.Molecular epidemiology of non-small cell lung cancer.Semin Respir Crit Care Med,2005,26(3):265-272.
[3] Fasching PA,Gayther S,Pearce L,et al.Role of genetic polymorphisms and ovarian cancer susceptibility[J].Mol Oncol,2009,3(2):171-181.
, 百拇醫(yī)藥
[4] Ohki R,Nemoto J,Murasawa H,et al.Reprimo,a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase[J].Biol Chem,2000,275(30):22627-22630.
[5] Bernal C,Aguayo F,Villarroel C,Vargas M,Díaz I,Ossandon FJ,Santibáez E,Palma M,Aravena E,Barrientos C,Corvalan AH.Reprimo as a potential biomarker for early detection in gastric cancer.Clin Cancer Res,2008 Oct 1,14(19):6264-9.
[6] Sato N,F(xiàn)ukushima N,Matsubayashi H,Iacobuzio-Donahue CA,Yeo CJ,Goggins M.Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.,2006 Jul 15,107(2):251-7
, 百拇醫(yī)藥
[7] Hamilton JP,Sato F,Jin Z,Greenwald BD,Ito T,Mori Y,Paun BC,Kan T,Cheng Y,Wang S,Yang J,Abraham JM,Meltzer SJ.Reprimo methylation is a potential biomarker of Barrett''s-Associated esophageal neoplastic progression.Clin Cancer Res,2006 Nov 15,12(22):6637-42.
[8] Takahashi T,Suzuki M,Shigematsu H,Shivapurkar N,Echebiri C,Nomura M,Stastny V,Augustus M,Wu CW,Wistuba II,Meltzer SJ,Gazdar AF.Aberrant methylation of Reprimo in human malignancies.Int J Cancer,2005 Jul 1,115(4):503-10.
, http://www.www.srpcoatings.com
[9] Suzuki M,Shigematsu H,Takahashi T,Shivapurkar N,Sathyanarayana UG,Iizasa T,F(xiàn)ujisawa T,Gazdar AF.Aberrant methylation of Reprimo in lung cancer.Lung Cancer,2005 Mar,47(3):309-14.
[10] 王海,等.5-AzadC聯(lián)合TSA對人胃癌SGC-7901細(xì)胞生長及 Reprimo基因表達(dá)的影響.安徽科技大學(xué)學(xué)報,2012,47(1):1-4
[11] 羅峻,等.S100A2、Reprimo在胃腺癌中的表達(dá)及其臨床意義.中華實(shí)驗(yàn)外科雜志,2008,25(6):754-755.
[12] 姜蕊,于世英.非小細(xì)胞肺癌中Reprimo以及14-3-3 Σ基因啟動子異常甲基化檢測.腫瘤防治研究,2009,36(2):106-109.
, http://www.www.srpcoatings.com
[13] Ye Z,Parry JM.Identification of polymorphisms in the human Reprimo gene using public EST data.Teratog Carcinog Mutagen[J],2002,22(6):485-493.
[14] Beasley WD,Beynon J,Jenkins GJ,et al.Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer:a case-control disease association study[J].Int J Colorectal Dis,2008,23(4):375-381., 百拇醫(yī)藥(陳賢華 胡宏波)